Replies to post #179166 on Biotech Values

[genisi]

Due to litigation settlements, regular Namenda goes generic in the US in Jan 2015.

Yes, and FRX are planning to stop marketing regular Namenda and excute a "final conversion" to the NAMENDA XR, currently holding 40% of users, before generic enters the market. My thinking was that Teva might take such action trying to switch as many patients from the daily to the thrice-weekly version. I'm sure they are considering this move but not sure it will help (in case you, jq, and others are right and payors would force patients switch back to cheaper daily generic).